Nonexudative Age-related Macular DegenerationPhase 1NCT01922128
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
A Phase 1 study of Nonexudative Age-related Macular Degeneration, run by MacuCLEAR, Inc. at 1 site in United States.
Trial summary
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals. Read more about this study
- Who is it for?
- Ages 50 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Nonexudative Age-related Macular Degeneration
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2013to Dec 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subjects ≥ 50 and ≤ 85 years of age.
- Women must be post-menopausal or surgically sterilized for 1 year or longer.
- Best corrected distance visual acuity of 1.0 logMAR of better in each eye (20/200 Snellen equivalent).
- Able and willing to sign informed consent and HIPAA authorization, follow study instructions and complete all study visits. A study visit may require several exams during the course of the day.
- Able and willing to discontinue the use of all ocular medication(s) except for artificial tears at least one week prior to receiving the study treatment and for the entire course of the study.
- General good health, as evaluated by the investigator, based on the medical history provided by the subject and any adjunctive testing carried out at the investigator's discretion.
Who cannot join
- Ophthalmic:
- Previous intravitreal injections of anti-VEGF therapies in either eye.
- History of diabetes and or diabetic retinopathy > 10 years.
- Ocular of laser surgery in either eye within 3 months of Visit 1.
- Ocular injection in either eye of any medication within 3 months of Visit 1.
- History of incisional glaucoma surgery in either eye.
Show all 21Show fewer
- Corneal, cataract or media opacification in either eye which limits an adequate view of the fundus in the opinion of the investigator.
- Contraindications to pupil dilation in either eye.
- Any ocular disease that requires ongoing treatment with topical ocular agents in either eye during the study. Patients using intermittent ocular medications must stop these medications for one week prior to Visit 2. Use of artificial tears 3 times daily or less for mild dry eye disease is allowed, but must not occur within ± 15 minutes from dosing of the investigational product).
- Corneal disease, corneal irregularity or scarring that in the opinion of the investigator would make it difficult to accurately measure intraocular pressure (IOP) or visualize intraocular anatomy in either eye.
- Presence of a Hudson-Stahli line in the corneal epithelium in either eye.
- General/Systemic:
- Female subjects who are menstruating.
- Prior participation (participation is defined as being randomized to an investigational product) in any other study in the last 30 days.
- Subjects unable to administer or have a caretaker administer the study eye drops.
- Subjects who are unable to follow instructions or are unwilling and considered physically unable to return for all study visits for the duration of the study.
- Clinically significant systemic disease that in the opinion of the investigator would interfere with the subject's ability to comply with the study requirements and or interpretation of the study results.
- Clinically significant abnormal results of laboratory tests, available to the investigator, which in the investigator's judgment would prohibit the subject from safe participation in this trial.
- Current or past use (more than 30 days) of chloroquine, hydroxychloroquine, chlorpromazine, thioridazine, quinine sulfate, clofazamine, cisplatin, carmustine, or deferoxamine.
- Uncontrolled blood pressure with systolic value ≥ 170 and diastolic ≥ 100 mmHg. Repeated measurements are allowed if in the investigator's opinion the time interval between recent antihypertensive medication dosing and blood pressure measurements was insufficient to provide for efficacious hypertension reduction.
- Subjects likely to undergo changes in systemic medications. All medications taken on a chronic basis must be stable for 30 days prior to Visit 2. Medications for an acute illness used within 30 days of Visit 1 must be discontinued prior randomization.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.
Read the detailed description
MC-1101 is a topical version of a previously approved anti-hypertensive drug that is intended to increase choroidal blood flow.
- A reduction of choroidal blood flow has been identified in patients with AMD
- This study will evaluate 0.5% and 1.0% potencies of MC-1101 delivered 2X per day.
- Being tested
- MC-1101, Placebo
- Keywords
- Non-exudative, dry AMD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MC-1101, PlaceboDrug
One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
| Study group | Role | What they receive |
|---|---|---|
| Drug, MC-1101 | Active comparator | One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days. Receives: Drug: MC-1101, Placebo |
| Placebo | Placebo comparator | One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient. Receives: Drug: MC-1101, Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
No significant ocular or systemic adverse events in any of the 20 study subjects
Assess the safety and tolerability of MC-1101 by evaluating the local ocular and systemic safety of MC-1101 0.5 % and 1 % in subjects in a dose escalation manner over 8 weeks of daily ocular exposure.
Measured: 56 total days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2013 (estimated)
- Study startSep 2013
- Primary completionNov 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nonexudative Age-related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- MacuCLEAR, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ken Sall, MD, Principal investigator, Sall Eye Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01922128
- Sponsor's protocol ID
- MC-1101-002
- Status last verified
- Apr 2014
- First submitted
- 7 Aug 2013
- Last updated
- 21 Apr 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals
- ClinicalTrials.gov ID
- NCT01922128
- Acronym / sponsor ID
- MC-1101-002
- Keywords
- Non-exudative, dry AMD
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- MacuCLEAR, Inc.Industry (pharma, biotech, devices)
- Study start
- Sep 2013
- Primary completion
- Nov 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 14 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.
Detailed description
MC-1101 is a topical version of a previously approved anti-hypertensive drug that is intended to increase choroidal blood flow.
- A reduction of choroidal blood flow has been identified in patients with AMD
- This study will evaluate 0.5% and 1.0% potencies of MC-1101 delivered 2X per day.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Drug, MC-1101 | Active comparator | Drug: MC-1101, PlaceboOne eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days. |
| Placebo | Placebo comparator | Drug: MC-1101, PlaceboOne eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient. |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subjects ≥ 50 and ≤ 85 years of age.
- Women must be post-menopausal or surgically sterilized for 1 year or longer.
- Best corrected distance visual acuity of 1.0 logMAR of better in each eye (20/200 Snellen equivalent).
- Able and willing to sign informed consent and HIPAA authorization, follow study instructions and complete all study visits. A study visit may require several exams during the course of the day.
- Able and willing to discontinue the use of all ocular medication(s) except for artificial tears at least one week prior to receiving the study treatment and for the entire course of the study.
Key exclusion criteria (21 listed)
- Previous intravitreal injections of anti-VEGF therapies in either eye.
- History of diabetes and or diabetic retinopathy > 10 years.
- Ocular of laser surgery in either eye within 3 months of Visit 1.
- Ocular injection in either eye of any medication within 3 months of Visit 1.
- History of incisional glaucoma surgery in either eye.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MC-1101, PlaceboOne drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo | Drug | Drug, MC-1101, Placebo |
Primary outcome
No significant ocular or systemic adverse events in any of the 20 study subjects
Time frame: 56 total days
Assess the safety and tolerability of MC-1101 by evaluating the local ocular and systemic safety of MC-1101 0.5 % and 1 % in subjects in a dose escalation manner over 8 weeks of daily ocular exposure.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2014.
Related trials for Nonexudative Age-related Macular Degeneration
RecruitingPhase 2
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Geographic Atrophy of the Macula
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Active, not recruiting
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
Geographic Atrophy
Recruiting
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
Dry Age-related Macular Degeneration
RecruitingObservational study
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Age-Related Macular Degeneration, Geographic Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ken Sall, MD principal investigator
Sall Eye Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study of Nonexudative Age-related Macular Degeneration, run by MacuCLEAR, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
No significant ocular or systemic adverse events in any of the 20 study subjects (time frame: 56 total days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2014; AzTrials last refreshed its copy on 7 Nov 2026.